HS-10375

Jiangsu Hansoh Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	HS-10375
Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HS-10375 CI brief — competitive landscape report
HS-10375 updates RSS · CI watch RSS
Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI